** Shares of Johnson & Johnson JNJ.N rise 0.3% to $244.40 after the company said it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania

** JNJ is on track to snap two straight sessions of losses

** The investment is part of its larger plans announced last year to scale up U.S. manufacturing amid President Donald Trump's tariff threats

** In March, the company announced a plan to invest more than $55 billion through early 2029 to build manufacturing facilities and the research infrastructure in the U.S.

** Other major drugmakers, including Eli Lilly LLY.N and AstraZeneca AZN.L, have also committed billions of dollars in investments to scale up their U.S. footprint in response to Trump's tariff threats

** Among 28 analysts covering JNJ, avg rating is "buy" and the median PT is $237, per LSEG data

** JNJ up 18% YTD vs S&P 500 health care index .SPXHC, which is up 1.3%